GLYXAMBI

• tagApproval42 co-mentions · 21 sources
• drugTRIJARDY XR21 co-mentions · 21 sources
• companyBoehringer Ingelheim Corp21 co-mentions · 21 sources
• tagSmall Molecule21 co-mentions · 21 sources
• drug(empagliflozin + linagliptin)21 co-mentions · 21 sources

Trials studying GLYXAMBI

• phase3A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failurerecruitingn=6,000
• N/ACLINICAL STUDY TO DETERMINE BIOEQUIVALENCE BETWEEN TWO ORAL MEDICATIONS OF EMPAGLIFLOZIN/METFORMIN IN 5 mg / 850 mg TABLETS UNDER FED CONDITIONS.completedn=42
• phase3A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heartrecruitingn=4,200
• phase3EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Diseaserecruitingn=11,800
• phase2A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Diseaseactive not recruitingn=416
• —Comparative Effectiveness of Empagliflozin in the USactive not recruitingn=230,000
• phase4Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combinationrecruitingn=800
• phase2Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)recruitingn=100